Published on
December 18, 2020
- 06:30 GMT
OSE Immunotherapeutics Receives €5.2 M in Public Funding for the Clinical Development of CoVepiT, its Second Generation COVID-19 ...
CoVepiT demonstrated generation of sentinel memory T cells with long-term protective effect against COVID-19 in preclinical and human ex vivo studies CoVepiT targets 11 virus proteins to prepare for potential mutations Clinical trial expected to start in …
Distribution channels:
Healthcare & Pharmaceuticals Industry, Media, Advertising & PR
...
